CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Candesartan +1 moredrug
Likely dose
Candesartan 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01678794
NCT01678794Phase 2Completed
CompareCT.gov

Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function

Mayo Clinic·interventional·Posted Sep 5, 2012·Updated Nov 18, 2021

In Brief

A Phase 2 clinical trial evaluating Candesartan and Placebo for Cardiorenal Syndrome (CRS). Completed, enrolled 33 participants across 1 site.

Detailed Summary

To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway. The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and renal dysfunction will improve renal function with increased sodium excretion, glomerular filtration rate and effective renal plasma flow and renal function reserve as compared to the response of placebo-treated subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiorenal Syndrome (CRS)
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 5, 2012
Enrollment StartFeb 1, 2012
Primary CompletionJun 29, 2016
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.8 years ago

Interventions

Candesartandrug

4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated

Placebodrug

4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated